Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting

Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA.
Journal of Viral Hepatitis (Impact Factor: 3.91). 05/2010; 18(7):474-81. DOI: 10.1111/j.1365-2893.2010.01327.x
Source: PubMed


Approximately 3.2 million persons are chronically infected with the hepatitis C virus (HCV) in the U.S.; most are not aware of their infection. Our objectives were to examine HCV testing practices to determine which patient characteristics are associated with HCV testing and positivity, and to estimate the prevalence of HCV infection in a high-risk urban population. The study subjects were all patients included in the baseline phase of the Hepatitis C Assessment and Testing Project (HepCAT), a serial cross-sectional study of HCV screening strategies. We examined all patients with a clinic visit to Montefiore Medical Center from 1/1/08 to 2/29/08. Demographic information, laboratory data and ICD-9 diagnostic codes from 3/1/97-2/29/08 were extracted from the electronic medical record. Risk factors for HCV were defined based on birth date, ICD-9 codes and laboratory data. The prevalence of HCV infection was estimated assuming that untested subjects would test positive at the same rate as tested subjects, based on risk-factors. Of 9579 subjects examined, 3803 (39.7%) had been tested for HCV and 438 (11.5%) were positive. The overall prevalence of HCV infection was estimated to be 7.7%. Risk factors associated with being tested and anti-HCV positivity included: born in the high-prevalence birth-cohort (1945-64), substance abuse, HIV infection, alcohol abuse, diagnosis of cirrhosis, end-stage renal disease, and alanine transaminase elevation. In a high-risk urban population, a significant proportion of patients were tested for HCV and the prevalence of HCV infection was high. Physicians appear to use a risk-based screening strategy to identify HCV infection.

Download full-text


Available from: Bryce David Smith
  • Source
    • "The hepatitis C virus (HCV) infects approximately 130–170 million people worldwide [1]; however, more than half of HCVinfected persons are unaware of their status [2]. Since 1998, the CDC has recommended that persons whose are at risk of infection routinely undergo anti-HCV testing [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rapid tests for the detection of antibodies to hepatitis C virus (anti-HCV) can facilitate access to diagnosis. This study aimed to evaluate the performance of rapid tests for anti-HCV detection in the sera, whole blood, and oral fluid samples from individuals with different endemicity profiles and risk behaviors. Three groups donated biological samples that were tested using three anti-HCV rapid tests (WAMA, Bioeasy and OraSure): (I) suspected cases of hepatitis C, (II) individuals who were living in remote areas in Brazil and (III) crack users and beauty professionals. Reproducibility, repeatability and cross-reactivity to other infectious agents (dengue, HIV, malaria, and syphilis) were also evaluated. In group I, specificities varied from 93.75% to 100% and sensitivities varied from 76.03% to 93.84% according to the EIA results. When anti-HCV/HCV RNA-reactive sera samples were considered true-positive HCV cases, the sensitivities and specificities varied from 86.3% to 99.09% and 93.75% to 100%, respectively. In group II, the OraSure rapid test presented the best performance. In group III, the Bioeasy assay performed best using saliva and whole blood and the OraSure assay performed best using oral fluid samples. The reproducibility and repeatability of the WAMA and Bioeasy tests were excellent. The level of concordance between the HCV EIAs and the rapid tests using samples that were reactive for other infectious agents varied from 82.35% to 100% for the WAMA assay and 94.11% to 100% for the Bioeasy assay. All of the rapid tests could be used to identify active HCV infection among individuals with different endemicity profiles and risk behaviors.
    Full-text · Article · Apr 2014 · Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology
  • Source
    • "Injection drug users (IDUs) have a high prevalence of viral hepatitis A, B, and C infection (HAV, HBV, HCV) in the U.S. (Hutin et al. 2005; Kuo, Sherman, Thomas, & Strathdee, 2004; Hennessey, Bangsberg, Weinbaum, & Hahn, 2009; Nelson et al., 2011). However, many IDUs do not know their HAV, HBV, and HCV serostatus (Carey et al. 2005; Gelberg et al. 2012; Reimer et al. 2006; Roblin, Smith, Weinbaum, & Sabin, 2011; Southern et al. 2011), may miss opportunities for prevention, and may be more likely to transmit these viruses to both drug using contacts and to non-drug using sexual and close contacts (Kuo et al. 2004; Thiede et al. 2007). While drug treatment programs are an ideal setting for viral hepatitis education, viral hepatitis is poorly addressed in U.S. opioid replacement therapy programs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the effectiveness of an educational method of providing viral hepatitis education for methadone maintenance patients. Four hundred forty participants were randomly assigned to either a control or a motivationally-enhanced viral hepatitis education and counseling intervention. Viral hepatitis A (HAV), B (HBV), and C (HCV) knowledge tests were administered at baseline, following each of two education sessions (post-education), and at a 3-month follow-up assessment. Results indicated a significant increase in knowledge of HAV, HBV, and HCV over time. No differences were found in knowledge between the intervention groups in knowledge acquisition regarding any of the hepatitis viruses suggesting that a motivational interviewing style may not augment hepatitis knowledge beyond standard counseling. A two-session viral hepatitis education intervention effectively promotes hepatitis knowledge and can be integrated in methadone treatment settings.
    Full-text · Article · Jan 2013 · Journal of substance abuse treatment
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Clinical and Translational Science Awards (CTSAs) were initiated to improve the conduct and impact of the National Institutes of Health's research portfolio, transforming training programs and research infrastructure at academic institutions and creating a nationwide consortium. They provide a model for translating research across disciplines and offer an efficient and powerful platform for comparative effectiveness research (CER), an effort that has long struggled but enjoys renewed hope under health care reform. CTSAs include study design and methods expertise, informatics, and regulatory support; programs in education, training, and career development in domains central to CER; and programs in community engagement.Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have entered a formal partnership that places their CTSA at a critical intersection for clinical and translational research. Their CTSA leaders were asked to develop a strategy for enhancing CER activities, and in 2010 they developed a model that encompasses four broadly defined "compartments" of research strength that must be coordinated for this enterprise to succeed: evaluation and health services research, biobehavioral research and prevention, efficacy studies and clinical trials, and social science and implementation research.This article provides historical context for CER, elucidates Einstein-Montefiore's CER model and strategic planning efforts, and illustrates how a CTSA can provide vision, leadership, coordination, and services to support an academic health center's collaborative efforts to develop a robust CER portfolio and thus contribute to the national effort to improve health and health care.
    Full-text · Article · Jun 2011 · Academic medicine: journal of the Association of American Medical Colleges
Show more